---
provider: claude_code
model: claude-haiku-4-5-20251001, claude-sonnet-5
cached: false
start_time: '2026-09-23T20:11:57.887495'
end_time: '2026-09-23T20:17:05.100532'
duration_seconds: 307.21
template_file: templates/disease_pathophysiology_research.md
template_sha: "1e7ea4ee817acfe1dda5f77fafe6f2e8b5927666"
template_variables:
  disease_name: Cutis Laxa Autosomal Recessive Type 2E
  mondo_id: MONDO:0030337
  category: Mendelian
provider_config:
  timeout: 1800
  max_retries: 3
  parameters:
    allowed_domains: []
    claude_executable: claude
    skip_permissions: false
    allowed_tools:
    - WebSearch
    - WebFetch
    add_dirs: []
    timeout: 1800
    min_report_chars: 200
    extra_args: []
run_metadata:
  models_used:
  - claude-haiku-4-5-20251001
  - claude-sonnet-5
  web_search_requests: 12
  num_turns: 29
  total_cost_usd: 1.6217326000000003
  session_id: fd65d8eb-852b-5a9d-91de-140beff025e2
  stop_reason: end_turn
  assistant_text_blocks: 3
fell_back: true
requested_provider: falcon
provider_attempts:
- provider: falcon
  succeeded: false
  error_type: ProviderBillingError
  status_code: 402
  remedy: the account is out of credits
  retryable: false
- provider: claude_code
  succeeded: true
citation_count: 6
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Cutis Laxa Autosomal Recessive Type 2E
- **MONDO ID:** MONDO:0030337 (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Cutis Laxa Autosomal Recessive Type 2E** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

I'll research this condition now using web search and fetch tools, then produce the full report inline.

No GeneReviews chapter exists for LTBP1-related cutis laxa (it's a 2021-described entity, likely too recent). Let me fetch the actual PMC article for full details.

# Cutis Laxa, Autosomal Recessive, Type 2E (ARCL2E) — Comprehensive Research Report

## Summary note on evidence base

This is a genetically and clinically ultra-rare, recently delineated Mendelian disorder. As of this search (September 2026), the entire published human evidence base traces to a single primary report — **Pottie et al., 2021, *American Journal of Human Genetics*, PMID:33991472** (erratum PMID:34861177, correcting an author's name; no other content changed) — describing 8 affected individuals from 4 unrelated consanguineous families. No independent replication cohort, GeneReviews chapter, natural-history study, or clinical management guideline was found in this search. All clinical/molecular claims below trace to that one paper unless otherwise cited; this is stated explicitly rather than manufactured from adjacent LTBP-family literature.

---

## 1. Disease Information

**Overview:** Autosomal recessive cutis laxa type 2E (ARCL2E) is caused by bi-allelic (homozygous) premature-truncating loss-of-function variants in **LTBP1** (latent transforming growth factor β [TGFβ]-binding protein 1). It presents with generalized cutis laxa (loose, redundant, inelastic skin), inguinal hernia, craniofacial dysmorphism, variable congenital heart defects, and a distinctive constellation of skeletal features — craniosynostosis, short stature, brachydactyly, clinodactyly, and syndactyly — that distinguishes it from other LTBP-related cutis laxa subtypes (Pottie et al. 2021, PMID:33991472).

**Key identifiers:**
- **OMIM:** #619451 — CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIE (ARCL2E) (https://omim.org/entry/619451)
- **Gene (OMIM):** *150390 — LTBP1
- **MONDO:** MONDO:0030337 — "cutis laxa, autosomal recessive, type 2E"; xrefs OMIM:619451, MedGen:1794154, UMLS:C5561944, GARD:0025543
- **HGNC:** LTBP1, HGNC:6714
- **NCBI Gene:** 4052 (chromosome 2p22.3)
- **Orphanet:** No LTBP1-specific ORPHA code was located in this search; the broader umbrella entry "Autosomal recessive cutis laxa type 2" is ORPHA:90350 (https://www.orpha.net/en/disease/detail/90350), which predates and does not specifically enumerate the 2E/LTBP1 subtype — flagged as a gap rather than assumed.
- **GeneReviews:** No chapter exists (confirmed by search; contrast with the existing ATP6V0A2-, LTBP4-, EFEMP2-, and ELN-related cutis laxa chapters).
- **ICD-10/ICD-11:** No disorder-specific code identified; general cutis laxa maps to ICD-10 Q82.8 (Other specified congenital malformations of skin), not subtype-resolved.

**Synonyms:** LTBP1-related cutis laxa syndrome (the name proposed by the discovering authors); ARCL2E; Cutis laxa, autosomal recessive, type IIE.

**Evidence provenance:** All published clinical data are aggregated case-series/cohort-level findings (structured phenotyping of 8 individuals across 4 families combined with in vitro fibroblast and in vivo zebrafish experiments), not EHR-derived population data.

---

## 2. Etiology

**Disease causal factor:** Purely genetic/Mendelian. Bi-allelic (homozygous, in all 4 reported families) premature-truncating variants in LTBP1 are the sole reported cause; no environmental, infectious, or multifactorial contribution is described.

**Genetic risk factors:**
- **Consanguinity** was present in all four reported families (Turkish, two Pakistani, Saudi Arabian), consistent with autosomal recessive inheritance and a private founder-type variant per family rather than a shared recurrent allele.
- The four reported variants are private to each family: c.4844del (p.Asn1615Ilefs*23), c.4431T>A (p.Cys1477*), c.3991_3995del (p.Thr1331Asnfs*20), c.1342C>T (p.Gln448*). All are absent from population allele-frequency databases (gnomAD/ExAC per the paper), consistent with each being ultra-rare/private rather than a population-level risk allele.
- No modifier genes, susceptibility loci, or GWAS signals for ARCL2E were found in this search — expected for an n=8 disorder.

**Environmental/lifestyle risk factors:** None reported; not applicable to this Mendelian, fully penetrant recessive disorder as currently described.

**Protective factors:** None reported in the literature located.

**Gene-environment interaction:** Not described; no CTD or other GxE database evidence was found for LTBP1 in this context.

---

## 3. Phenotypes

Frequencies below are drawn from the 8 individuals (4 families) in Pottie et al. 2021 and should be read as a small-cohort case series, not a population-representative prevalence.

| Phenotype | Frequency (of 8) | Category | Suggested HPO term* |
|---|---|---|---|
| Cutis laxa (generalized, loose/redundant skin) | 8/8 (100%) | Physical/dermatologic | HP:0000973 Cutis laxa |
| Short stature | 8/8 (100%) | Physical/growth | HP:0004322 Short stature |
| Wide nasal bridge | 8/8 (100%) | Craniofacial | HP:0000431 Wide nasal bridge |
| Coarse facial features | 7/8 (87.5%) | Craniofacial | HP:0000280 Coarse facial features |
| Deep palmar creases | 7/8 (87.5%) | Physical | HP:0006191 (deep palmar crease term family) |
| Brachydactyly | 7/8 (87.5%) | Skeletal | HP:0001156 Brachydactyly |
| Fifth-finger clinodactyly | 7/8 (87.5%) | Skeletal | HP:0004209 Clinodactyly of the 5th finger |
| Long eyelashes | 7/8 (87.5%) | Craniofacial | HP:0000527 Long eyelashes |
| Craniosynostosis | 6/8 (75%) | Skeletal/neurologic | HP:0001363 Craniosynostosis |
| Proptosis | 6/8 (75%) | Craniofacial/ophthalmologic | HP:0000520 Proptosis |
| Inguinal hernia | 5/8 (62.5%) | Connective tissue | HP:0000023 Inguinal hernia |
| Syndactyly | 5/8 (62.5%) | Skeletal | HP:0001159 Syndactyly |
| Congenital heart defect (ASD, valvular insufficiency, LVH) | 3/8 (37.5%) | Cardiovascular | HP:0001631 Atrial septal defect; HP:0001636 Tricuspid regurgitation |
| Hearing loss | 3/8 (37.5%) | Sensory | HP:0000365 Hearing impairment |
| Learning difficulties | 3/8 (37.5%) | Neurodevelopmental | HP:0001328 Specific learning disability (or HP:0001256 Intellectual disability, mild, per individual) |
| Feeding problems / gastroesophageal reflux | 3/8 (37.5%) | Gastrointestinal | HP:0002020 Gastroesophageal reflux |
| Optic nerve hypoplasia | 3/8 individuals | Ophthalmologic | HP:0000609 Optic nerve hypoplasia |
| Cranial-nerve-palsy ophthalmoplegia | 2/8 | Neurologic | HP:0000602 Ophthalmoplegia |
| Urological abnormalities | 2/8 (25%) | Genitourinary | HP:0000119 Abnormality of the genitourinary system (nonspecific; specific term not stated in source) |
| "Copper-beaten" calvarium (radiographic) | Reported (F1:IV-2, age 3y) | Skeletal/radiographic | HP:0002514 Wormian bones / copper-beaten skull family term |

*HPO term suggestions are drawn from general knowledge of the ontology, not confirmed against a live HPO lookup in this session — they should be verified before curation (per this repository's Ontology Term Contract, no CURIE here should be treated as pre-validated).

**Onset/course:** Congenital/early-childhood presentation (cutis laxa and craniofacial features apparent from infancy; craniosynostosis identified from roughly 6 months to childhood). Age at evaluation in the cohort ranged 1 year 6 months to 17 years 5 months. The paper does not describe a degenerative or progressive course over that observation window — features appear structural/developmental rather than progressively worsening, though formal longitudinal natural-history data do not exist.

**Severity/variability:** Variable — e.g., cardiac involvement in only 3/8, learning difficulties in 3/8 (one individual, F2:V-4, had severe intellectual disability of otherwise unclear etiology), and the two zebrafish allelic lines showed genotype-dependent severity, foreshadowing likely variant-dependent human variability (see Mechanism section — C-terminal vs. N-terminal truncations differ molecularly).

**Quality of life impact:** Not formally measured (no EQ-5D/SF-36/disease-specific instrument use reported); qualitatively, skeletal (craniosynostosis, short stature), cardiac, and hearing/vision involvement imply likely burden requiring multidisciplinary surveillance, but no quantitative QoL data exist.

---

## 4. Genetic / Molecular Information

**Causal gene:** LTBP1 (HGNC:6714; OMIM *150390; chr2p22.3).

**Variants identified (Pottie et al. 2021):**

| Family (origin) | HGVS (cDNA) | Protein | Exon | Domain | Mechanism class |
|---|---|---|---|---|---|
| F1 (Turkish) | c.4844del | p.Asn1615Ilefs*23 | 29 | 3rd EGF-like domain | C-terminal truncation |
| F2 (Pakistani) | c.4431T>A | p.Cys1477* | 26 | 13th calcium-binding EGF domain | C-terminal truncation |
| F3 (Pakistani) | c.3991_3995del | p.Thr1331Asnfs*20 | 23 | 12th calcium-binding EGF domain | C-terminal-region truncation |
| F4 (Saudi Arabian) | c.1342C>T | p.Gln448* | 7 | 2nd EGF-like domain | N-terminal truncation |

All variants: homozygous, segregated with affected/carrier status within each family, absent from population databases, and predicted deleterious by multiple in silico tools (per the source; specific tool names not extracted in this pass).

**Variant classification (ACMG/AMP):** Not explicitly stated as formal ACMG tiers in the extracted material; functionally validated as pathogenic via segregation plus in vitro/in vivo functional work, which is the strongest evidentiary combination even absent an explicit "Pathogenic" tier label in the summary retrieved.

**Functional consequence — this is the mechanistically important part of the paper, and it is genotype-dependent:**
- **N-terminal truncation (F4, p.Gln448*):** transcript triggers nonsense-mediated decay (NMD) — largely rescued by cycloheximide in vitro — producing **complete loss of LTBP1 protein**. In patient fibroblasts this reduced FBN1 (fibrillin-1) mRNA but did **not** alter TGFβ levels, ECM assembly, or CTGF/POSTN (TGFβ target gene) expression — i.e., a straightforward **loss-of-function/haploinsufficiency-like** signature with apparent partial functional redundancy from other LTBP paralogs.
- **C-terminal truncations (F1, and by extension F2/F3):** transcript escapes NMD (normal mRNA levels), producing a **truncated protein retaining N-terminal sequence but lacking C-terminal EGF-like/TGFβ-binding domains**. This truncated protein has reduced binding affinity for fibrillin-1/-2 N-termini, is only loosely anchored in the microfibrillar network, and is associated with a **gain-of-abnormal-function/dominant-negative-like matrix phenotype**: increased ECM deposition (increased collagen I/III and fibrillin-1 fibers, abolished EFEMP2/fibulin-4 fibers, compensatory increase in LTBP2 fibers), elevated total TGFβ in conditioned media, increased phospho-Smad2/Smad2 ratio, and upregulated CTGF/POSTN — i.e., **excessive TGFβ activation and signaling**.

This two-mechanism split (LOF vs. altered/gain-of-abnormal-function depending on truncation position) is the central molecular finding and should be modeled as two distinct pathophysiological branches rather than a single uniform "loss of LTBP1" mechanism.

**Population frequency:** All four variants reported as absent from population databases (private/founder variants); no carrier-frequency or population-prevalence estimate exists.

**Somatic vs. germline:** Germline only; no somatic/oncologic association reported.

**Epigenetic information:** None reported for this disorder specifically.

**Chromosomal abnormalities:** None reported; disease is due to small indel/nonsense sequence variants, not CNV or structural rearrangement.

---

## 5. Environmental Information

No environmental, lifestyle, or infectious contributory factors were identified in the literature located. This is consistent with ARCL2E being a fully genetically determined Mendelian disorder as currently characterized.

---

## 6. Mechanism / Pathophysiology

### Ordered causal chain (two parallel branches by variant position)

**Branch A — N-terminal truncating variant (e.g., F4 p.Gln448*):**
1. Homozygous nonsense variant in LTBP1 exon 7 → premature stop codon early in the transcript.
2. Transcript is targeted by nonsense-mediated decay → **near-complete loss of LTBP1 protein** (demonstrated: mRNA abolished, partially rescued by cycloheximide, confirming NMD).
3. Loss of LTBP1 protein reduces FBN1 (fibrillin-1) mRNA expression in patient dermal fibroblasts (mechanism of this specific cross-talk not further dissected in the source).
4. Despite LTBP1 loss, TGFβ sequestration/activation and canonical Smad2 signaling remain largely **unaltered**, and EFEMP2 (fibulin-4) incorporation into fibers is normal — inferred functional compensation by other LTBP paralogs (LTBP2/3/4), stated as a proposed explanation rather than directly proven.
5. Net result: connective-tissue/skeletal phenotype (cutis laxa, craniofacial and skeletal dysmorphology) without a demonstrable excess-TGFβ signature — this branch is closer to simple structural LTBP1 haploinsufficiency at the microfibril level.

**Branch B — C-terminal truncating variant (e.g., F1 p.Asn1615Ilefs*23):**
1. Homozygous frameshift/nonsense variant in a 3′ exon (29) encoding EGF-like/TGFβ-binding domains → transcript escapes NMD → a truncated LTBP1 protein is produced and retained (not simply absent).
2. Truncated LTBP1 has reduced binding affinity for the N-terminal regions of fibrillin-1 and fibrillin-2 → the mutant protein is only loosely anchored within the fibrillin microfibrillar network (demonstrated in patient fibroblasts: rudimentary LTBP1 fibers).
3. This loose anchoring is associated with abnormal ECM remodeling: increased fibrillin-1 deposition, abolished EFEMP2/fibulin-4 fiber incorporation (fibulin-4 normally bridges tropoelastin to microfibrils for elastin cross-linking), and a compensatory increase in LTBP2 fibers.
4. Disrupted latent-complex sequestration leads to **excess release/activation of TGFβ** → elevated total TGFβ in conditioned media and an increased phospho-Smad2/Smad2 ratio → **canonical TGFβ/Smad2 pathway hyperactivation**.
5. TGFβ target genes CTGF and POSTN are transcriptionally upregulated, and collagen I/III fiber deposition is increased in the ECM.
6. Net result: excessive/dysregulated ECM deposition combined with impaired elastic-fiber (elastin/fibulin-4) incorporation — electron microscopy in an affected individual showed elastic fibers with peripheral microfibril infiltration and mild elastin fragmentation, consistent with a structurally abnormal elastic fiber network → clinically manifests as cutis laxa (loose, inelastic skin), and, via TGFβ-driven effects on bone/connective tissue, contributes to the skeletal phenotype (craniosynostosis, short stature, brachydactyly).

**Convergent downstream node:** Both branches converge on **disrupted elastic-fiber/microfibril assembly and connective-tissue extracellular matrix organization** in skin, and on **abnormal skeletal ECM/ossification**, even though the upstream molecular signature (TGFβ signaling normal vs. hyperactivated) differs — an important nuance for pathograph modeling: the two variant classes should probably be represented as distinct genetic_context/functional_impact_category nodes (one closer to LOSS_OF_FUNCTION, one closer to a DOMINANT_NEGATIVE/altered-protein mechanism) converging on a shared downstream "abnormal elastic fiber/microfibril assembly" node, rather than collapsed into one edge.

### Cellular/tissue mechanism supporting the chain
- **Cell type:** dermal fibroblasts (CL:0002620 dermal fibroblast, or general CL:0000057 fibroblast) are the direct cellular substrate studied; these are the ECM-secreting cells responsible for depositing collagen, fibrillin microfibrils, and elastin.
- **In vivo zebrafish validation** (two independent CRISPR ltbp1 mutant lines, ltbp1−/−Δ29 and ltbp1−/−Δ35): both show **abnormal collagen fibrillogenesis** in skin (disordered, "folded plywood-like" collagen architecture) and intervertebral ligaments (chaotic fibril assembly), plus **ectopic (intramembranous) bone formation** on vertebral neural/haemal arches. The Δ29 line (retaining fewer C-terminal TGFβ-binding domains) additionally shows **decreased tissue mineral density** and voluminous, hypomineralized vertebrae, while the Δ35 line (different domain loss) has normal mineral density — reinforcing that phenotype severity tracks with exactly which C-terminal domains are lost, paralleling the human N- vs. C-terminal split. Neither zebrafish line shows craniosynostosis or cardiac dysfunction, marking a translational gap (some human-specific features are not recapitulated in fish).

### Suggested ontology terms for pathophysiology nodes
- **GO biological process:** GO:0007179 (TGF-beta receptor signaling pathway), GO:0048251 (elastic fiber assembly), GO:0043588 (skin development), GO:0001501 (skeletal system development), GO:0030199 (collagen fibril organization).
- **GO molecular function:** binding to fibrillin/TGFβ (specific term e.g. GO:0050431 transforming growth factor beta binding — verify before use).
- **GO cellular component:** GO:0005576 extracellular region / GO:0005578 proteinaceous extracellular matrix.
- **CL:** CL:0000057 fibroblast (dermal fibroblast subtype).
- **CHEBI:** not directly applicable (protein-level, not small-molecule, mechanism).

(All ontology suggestions above are leads for curator lookup, not verified CURIEs.)

---

## 7. Anatomical Structures Affected

- **Organ level (primary):** Skin/integument (generalized cutis laxa); craniofacial skeleton (craniosynostosis, coarse facies); axial/appendicular skeleton (short stature, brachydactyly, clinodactyly, syndactyly).
- **Organ level (secondary/variable):** Cardiovascular system (atrial septal defect, valvular insufficiency, left ventricular hypertrophy in 3/8); inguinal/abdominal wall (hernia); auditory system (hearing loss); visual system (optic nerve hypoplasia, proptosis, ophthalmoplegia); gastrointestinal (feeding problems/GERD); genitourinary (unspecified abnormalities in 2/8); central nervous system (learning difficulties in a subset).
- **Body systems involved:** integumentary, skeletal, cardiovascular, sensory (auditory + ophthalmologic), gastrointestinal, genitourinary, and (variably) neurodevelopmental.
- **Tissue/cell level:** dermal connective tissue and dermal fibroblasts (site of the primary ECM/microfibril defect); craniofacial sutures (site of craniosynostosis); intervertebral ligament and vertebral bone (per zebrafish data, translatable by analogy to the human skeletal phenotype).
- **Subcellular/ECM level:** extracellular microfibrils (fibrillin-1/-2 network) and elastic fibers (elastin core with fibulin-4/EFEMP2 cross-bridging) — LTBP1 itself is a secreted, extracellular (not intracellular organelle-localized) matrix protein.
- **Suggested UBERON terms:** UBERON:0002097 (skin of body), UBERON:0002020 (gray matter — not relevant), UBERON:0003129 (skull), UBERON:0002037 (cerebellum — not relevant); more precisely: UBERON:0001519 (dermis), UBERON:0002542 (chondrocranium/craniofacial skeleton term — verify exact term), UBERON:0000948 (heart), UBERON:0001690 (ear), UBERON:0000966 (retina/optic nerve region — verify), UBERON:0001555 (digestive tract). These are leads only.
- **Laterality:** Not specifically discussed as unilateral vs. bilateral; craniosynostosis affects "variable cranial sutures" (implying no fixed single-suture pattern), and skeletal hand features (brachydactyly, syndactyly, clinodactyly) are generally described as affecting the hands without a stated laterality preference in the summarized material.

---

## 8. Temporal Development

- **Onset:** Congenital/early childhood. Cutis laxa and craniofacial dysmorphism are present from early life; craniosynostosis is identified in infancy to early childhood in the cohort (evaluation ages spanning 6 months to 17 years 5 months, with radiographic "copper-beaten" calvarium documented at age 3 years in one individual, reflecting raised intracranial pressure secondary to craniosynostosis).
- **Onset pattern:** Structural/developmental (present from birth or early infancy) rather than acute or episodic.
- **Progression:** No formal staging system exists. The published cohort (cross-sectional, ages 1.5–17.4 years) does not describe a clearly progressive deteriorating course over that age range for the core features, but a rigorous prospective natural-history study has not been performed — this is an evidence gap, not a documented "stable" course.
- **Disease course pattern:** Best characterized as a stable structural/congenital multisystem syndrome based on available cross-sectional data; not reported as relapsing-remitting or episodic.
- **Duration:** Presumed lifelong (genetic, structural disorder); no data on adult natural history, since the oldest reported individual was 17 years 5 months at evaluation.
- **Remission:** None described or expected given the structural nature of the defect.
- **Critical periods:** Prenatal/early postnatal connective-tissue and craniofacial-suture development is implicated as the critical window (craniosynostosis and cutis laxa both reflect early developmental ECM assembly defects), but no intervention-timing data exist.

---

## 9. Inheritance and Population

- **Epidemiology:** No prevalence or incidence figures exist for ARCL2E specifically. It is an ultra-rare disorder — only 8 individuals from 4 families reported in the literature located by this search. (Using this repository's `PrevalenceClassEnum`, this would likely be recorded as `NOT_YET_DOCUMENTED` rather than assigned a numeric band, since no denominator-based estimate has been published.)
- **Inheritance pattern:** Autosomal recessive (HP:0000007), confirmed in all 4 families by biallelic homozygosity with parental consanguinity and segregation with carrier/affected status.
- **Penetrance:** Not formally assessed (small pedigree data); all homozygotes reported were symptomatic, consistent with high/complete penetrance in the reported families, but this has not been established at a population level.
- **Expressivity:** Clearly **variable** — e.g., cardiac defects in only 3/8, craniosynostosis in 6/8, learning difficulties in 3/8 — and appears to have a genotype-correlated component (N-terminal vs. C-terminal truncation producing molecularly distinct signatures, as detailed in Mechanism above), though the paper's small family-level sample size limits firm genotype-phenotype correlation claims.
- **Genetic anticipation:** Not applicable/not reported (not a repeat-expansion disorder).
- **Germline mosaicism:** Not reported.
- **Founder effects:** Each of the 4 families carries a distinct, private variant — no shared founder allele across the reported cohort; each family's variant is presumably a private/founder allele within that specific consanguineous kindred.
- **Consanguinity role:** Central — all 4 families were consanguineous, which is both how the ultra-rare homozygous genotypes arose and likely why they were detectable via exome/genome sequencing in first identifying this gene-disease relationship.
- **Carrier frequency:** Not established; each variant is described as absent from population allele-frequency databases, implying very low (unmeasurable at current cohort sizes) carrier frequency.
- **Affected populations/geographic distribution:** Families originated from Turkey, Pakistan (two families), and Saudi Arabia — consistent with ascertainment in populations/practices with higher consanguinity rates, but this should not be read as evidence of a higher true prevalence in these populations versus simply where consanguineous homozygosity (and thus detection) occurred.
- **Sex ratio / age distribution:** Not reported in extracted material; specific per-individual sex breakdown was not captured in this pass and should be confirmed from the primary paper before curation.

---

## 10. Diagnostics

- **Genetic testing (primary diagnostic modality):** Molecular confirmation of biallelic LTBP1 truncating variants via exome or genome sequencing was how all 4 families were diagnosed (research/discovery cohort context — trio/family exome sequencing). No dedicated clinical gene panel or GTR listing was specifically verified in this search (a generic GTR fetch failed due to an incorrect internal ID); LTBP1 sequencing would be expected to be captured within broader "cutis laxa" or "connective tissue disorder" NGS panels offered by clinical laboratories, though this was not directly confirmed.
- **Chromosomal microarray/karyotype:** Not indicated as a primary diagnostic tool — disease is due to small sequence variants, not CNV.
- **Imaging:** Skull/craniofacial radiography or CT to assess craniosynostosis and the "copper-beaten" calvarial pattern (a radiographic sign of chronically raised intracranial pressure from craniosynostosis); echocardiography for the cardiac defects (ASD, valvular insufficiency, LVH) identified in a subset.
- **Histopathology/electron microscopy:** Skin biopsy with transmission electron microscopy demonstrated abnormal elastic fibers (microfibril infiltration at the fiber periphery, mild elastin fragmentation) in at least one affected individual — a research-grade rather than routine clinical diagnostic finding, but potentially supportive when genetic testing is equivocal.
- **Functional/laboratory correlates:** Elevated TGFβ / phospho-Smad2 signaling and altered ECM protein deposition were demonstrated in **cultured patient dermal fibroblasts** specifically for C-terminal-variant carriers — a research assay, not an established clinical biomarker or diagnostic test.
- **Differential diagnosis:** Other autosomal recessive cutis laxa subtypes — ARCL1A/B/C (FBLN5, EFEMP2/FBLN4, LTBP4), ARCL2A/B/C/D (ATP6V0A2, PYCR1, ATP6V1E1, ATP6V1A), ARCL3 (ALDH18A1/PYCR1, De Barsy-overlap phenotype), and autosomal dominant cutis laxa (ELN). ARCL2E is distinguished from LTBP4-related ARCL1C by its more prominent craniofacial dysmorphology and skeletal features (craniosynostosis, short stature, brachydactyly, syndactyly) rather than the pulmonary emphysema/diverticular disease more typical of LTBP4-CL, and from the ATP6V0A2/ATP6V1-related "metabolic" ARCL2 subtypes by the absence (as far as reported) of a glycosylation/metabolic biomarker signature.
- **Screening:** No newborn, carrier, or population screening program exists for this disorder given its extreme rarity and recent (2021) discovery.

---

## 11. Outcome / Prognosis

No formal survival, mortality, or long-term outcome data exist — the oldest reported individual was 17 years 5 months at last evaluation, with no report of premature mortality in the cohort. Complications documented include: congenital heart defects (a minority, 3/8, generally described as "moderate" rather than severe/critical), hearing loss, optic nerve hypoplasia/ophthalmoplegia, inguinal hernia (requiring surgical repair, though this was not explicitly stated as performed), and learning difficulties/intellectual disability in a subset. No disease-specific quality-of-life instrument data, formal prognostic biomarkers, or long-term functional outcome studies were located. This should be flagged in any KB entry as a genuine evidence gap rather than inferred as "good prognosis" by absence of reported deaths in a small, young cohort.

---

## 12. Treatment

No disease-specific treatment trials, approved therapies, or published management guideline was located for ARCL2E — expected given its 2021 discovery and n=8 published cohort. Based on the general pattern for syndromic connective-tissue/cutis laxa disorders (extrapolated, not disease-specific evidence, and should be labeled as such in any KB entry) and on the specific comorbidities documented in the founding cohort, plausible/inferred multidisciplinary management would include:

- **Craniofacial/neurosurgical:** surgical correction of craniosynostosis, ideally with monitoring for raised intracranial pressure (the "copper-beaten" skull sign implies a subset develop this) — NCIT:C15329 (Surgical Procedure) as a generic treatment_term.
- **Cardiology:** surveillance echocardiography and, if indicated, surgical/interventional management of ASD or valvular disease — NCIT:C15329.
- **Surgical hernia repair** for inguinal hernia — NCIT:C15329.
- **Audiology/otolaryngology:** hearing evaluation and hearing-aid provision as indicated — NCIT:C15302 (Physical Therapy) not applicable; a hearing-device qualifier would follow this repository's device-annotation pattern (action term + NCIT:C16830 Medical Device qualifier), if curated.
- **Ophthalmology:** surveillance for optic nerve hypoplasia and management of ophthalmoplegia.
- **Developmental/educational support:** for the subset with learning difficulties.
- **Genetic counseling** for consanguineous families given the autosomal recessive, high-penetrance inheritance pattern — NCIT:C15240 (Genetic Counseling).

**No pharmacotherapy, gene therapy, RNA-based therapy, or clinical trial (ClinicalTrials.gov / WHO ICTRP) specific to ARCL2E or LTBP1 was found.** Given the mechanistic finding that C-terminal variants drive excess TGFβ/Smad2 signaling, an anti-TGFβ pharmacological strategy (e.g., angiotensin receptor blockade, as used investigationally in other TGFβ-dysregulated connective tissue disorders such as Marfan syndrome/Loeys-Dietz spectrum) is a plausible future avenue *by mechanistic analogy only* — this is explicitly a hypothesis, not a reported or trialed intervention for this disease, and should not be curated as an established treatment.

---

## 13. Prevention

No primary, secondary, or tertiary prevention strategy, screening program, or prophylactic intervention specific to ARCL2E was located. The only applicable "prevention" lever identified in the literature is **genetic counseling and reproductive risk assessment for consanguineous couples/carrier relatives** in families with a known LTBP1 variant — standard practice for autosomal recessive disorders identified through consanguineous-family sequencing, not a disease-specific published protocol.

---

## 14. Other Species / Natural Disease

No naturally occurring LTBP1-associated cutis laxa-like disease in non-human species (companion animals, livestock, wildlife) was identified in this search — no OMIA entry or veterinary case series was found. This is a gap; it may reflect a genuine absence of recognized natural disease, or simply that it has not yet been looked for/reported, and should not be asserted either way without a dedicated OMIA search.

- **Orthologous gene:** Mouse *Ltbp1* (MGI:109151), used experimentally (see Model Organisms below) but representing an induced/engineered model, not naturally occurring disease.
- **Comparative biology:** LTBP1 is part of the evolutionarily conserved LTBP/fibrillin microfibril-TGFβ regulatory system also present in zebrafish (used experimentally, see below) — the pathway itself (latent TGFβ sequestration in ECM microfibrils) is broadly conserved across vertebrates, supporting mechanistic (not disease-natural-history) cross-species relevance.

---

## 15. Model Organisms

**Zebrafish (Danio rerio) — disease-specific, from the founding paper:**
- Two independent CRISPR-generated *ltbp1* mutant lines were created and directly validate the human gene-disease relationship (Pottie et al. 2021, PMID:33991472):
  - *ltbp1*−/−Δ29 (1 bp deletion, exon 29 — analogous region to human C-terminal-truncating variants, lacking C-terminal TGFβ-binding domains)
  - *ltbp1*−/−Δ35 (10 bp deletion, exon 35 — lacking terminal EGF domains)
- **Shared phenotypes (both lines):** abnormal collagen fibrillogenesis in skin (disorganized "folded plywood-like" architecture) and intervertebral ligaments (chaotic fibril assembly); ectopic intramembranous bone formation on vertebral neural/haemal arches; normal weight, length, Mendelian transmission, and no premature mortality.
- **Line-specific:** Δ29 additionally shows decreased tissue mineral density and voluminous, hypomineralized vertebrae (implicating the specific C-terminal TGFβ-binding domains retained/lost); Δ35 has normal mineral density.
- **Model limitations (explicitly relevant for a HUMAN_MODEL_MISMATCH-type curation note):** neither zebrafish line reproduces craniosynostosis or cardiac dysfunction seen in some human patients, so the model **partially** but not fully recapitulates the human phenotype — skin/skeletal ECM and vertebral bone phenotypes translate well; craniofacial suture and cardiac phenotypes do not, at least in the alleles tested.

**Mouse (Mus musculus) — gene-function models, not disease-specific:**
- Total *Ltbp1* knockout mice: shortened long bones (skeletal phenotype partially overlapping the human short-stature/brachydactyly features).
- *Ltbp1*ΔEx5 (exon-5-deletion) mice: minor craniofacial abnormalities and long-bone shortening.
- *Ltbp1*-deficient female mice: subfertility and ovarian cyst formation, proposed to reflect defective TGFβ-dependent follicular wound healing (a phenotype not reported/assessed in the human cohort, and of uncertain relevance to the human disease given no female-fertility endpoint was evaluated in the 2021 paper).
- These mouse models predate and are not specific to the 2021 human gene-disease discovery; they establish LTBP1's broader developmental roles (craniofacial, skeletal, cardiovascular per general gene-function literature, reproductive) but were not generated to model ARCL2E's specific truncating-variant genotypes, and direct translational claims from them to the human disorder should be treated as inferential (model-gene-function evidence), not disease-specific model validation.
- No induced pharmacological, surgical, or environmental (non-genetic) model was identified.
- No iPSC-derived or organoid model specific to ARCL2E/LTBP1 was found in this search.

---

## Citation List (as verified in this session)

1. **Pottie L, Adamo CS, Beyens A, Lütke S, Tapaneeyaphan P, De Clercq A, Salmon PL, De Rycke R, Gezdirici A, Gulec EY, Khan N, Urquhart JE, Newman WG, Metcalfe K, Efthymiou S, Maroofian R, Anwar N, Maqbool S, Rahman F, Altweijri I, Alsaleh M, Abdullah SM, Al-Owain M, Hashem M, Houlden H, Alkuraya FS, Sips P, Sengle G, Callewaert B.** "Bi-allelic premature truncating variants in LTBP1 cause cutis laxa syndrome." *Am J Hum Genet.* 2021. **PMID:33991472**, PMCID:PMC8206382. https://pubmed.ncbi.nlm.nih.gov/33991472/ | https://www.cell.com/ajhg/fulltext/S0002-9297(21)00147-6
   - Abstract quoted verbatim above (Europe PMC record).
2. **Erratum** to the above: PMID:34861177, PMCID:PMC8715164 (author-name correction only; no scientific content change) — confirmed via Europe PMC metadata but abstract text not separately available (correction notices typically carry none).
3. **OMIM #619451** — CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIE; ARCL2E. https://omim.org/entry/619451
4. **OMIM *150390** — LATENT TRANSFORMING GROWTH FACTOR-BETA-BINDING PROTEIN 1; LTBP1. https://omim.org/entry/150390
5. **MONDO:0030337** (OLS4 record; label "cutis laxa, autosomal recessive, type 2E"; xrefs OMIM:619451, MedGen:1794154, UMLS:C5561944, GARD:0025543). https://www.ebi.ac.uk/ols4/ontologies/mondo
6. **Orphanet ORPHA:90350** — "Autosomal recessive cutis laxa type 2" (umbrella entry, not 2E-specific). https://www.orpha.net/en/disease/detail/90350

**Explicitly not found / gaps to flag rather than paper over:**
- No GeneReviews chapter.
- No dedicated Orphanet entry for the 2E/LTBP1 subtype specifically (only the pre-existing "type 2" umbrella).
- No second independent human cohort or case report since the 2021 founding paper.
- No prevalence/incidence estimate, no natural-history study beyond the cross-sectional founding cohort, no clinical trial, no published management guideline.
- No confirmed OMIA/veterinary natural-disease entry.
- GTR single-gene-testing panel listing was not successfully retrieved (tool/ID error) and should be re-checked directly against the Genetic Testing Registry before a KB entry asserts specific panel availability.

## Reference Validation

Checked with `linkml-reference-validator` 0.2.1.

| Outcome | Count |
| --- | --- |
| References checked | 4 |
| Resolved | 4 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 4 |
| On topic | 4 |
| Off topic | 0 |

All extracted references resolved successfully.
